STATE UNIVERSITY OF NEW YORK AT BUFFALO
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia is a funding opportunity from STATE UNIVERSITY OF NEW YORK AT BUFFALO, up to 428904, closing January 31, 2028.
Jan 31, 2028
(549d left)Overview
This project utilizes mechanistic pharmacokinetic / pharmacodynamic modeling to guide the development of new therapeutic strategies, and new therapeutic agents, to improve the safety and efficacy of antibody-drug conjugate (ADC) therapy for acute myeloid leukemia (AML). The project will generate new monoclonal…